ENDONOVO THERAPEUTICS, INC.
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $135.4K | $73.1K | $165.8K | $310.2K | $83.3K | — | — |
| Cost of Revenue | — | $10.0K | $15.0K | $65.4K | $93.4K | $12.9K | — | — |
| Gross Profit | — | $125.4K | $58.1K | $100.4K | $216.8K | $70.3K | — | — |
| Gross Margin | — | 92.6% | 79.5% | 60.6% | 69.9% | 84.5% | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | $0 | $3.3K | $153.1K | $274.3K | $115.2K | $0 |
| SG&A Expense | — | — | — | — | — | — | — | — |
| Operating Income | — | $-3.3M | $-2.2M | $-2.9M | $-3.8M | $-4.2M | $-4.6M | $-5.4M |
| Operating Margin | — | -2,411.7% | -3,045.7% | -1,756.5% | -1,228.1% | -4,995.3% | — | — |
| Interest Expense | — | — | $941.6K | $2.1M | $17.0K | — | — | — |
| Pretax Income | — | $-18.5M | $-3.1M | $-395.6K | $-17.3M | $-6.4M | $-10.8M | $-5.3M |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-18.5M | $-3.1M | $-395.6K | $-17.3M | $-6.4M | $-10.8M | $-5.3M |
| Net Margin | — | -13,649.2% | -4,247.2% | -238.6% | -5,582.4% | -7,729.5% | — | — |
| EPS (Basic) | — | $-0.13 | $-0.03 | $-0.02 | $-12.42 | $-8.88 | $-0.02 | $-0.03 |
| EPS (Diluted) | — | — | $-0.03 | $-0.02 | $-12.42 | $-8.88 | $-0.02 | $-0.03 |
| Shares Outstanding (Basic) | 270.3M | 139.2M | 119.7M | 49.1M | 2.4M | 862.1M | 633.9M | 268.7M |
| Shares Outstanding (Diluted) | 270.3M | 139.2M | 119.7M | 49.1M | 2.4M | 862.1M | 633.9M | 268.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |